Skip to content
TriangleGet started
← Full study record

NCT01797523 · OUTCOME

Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma · Source last updated 2026-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
93 months

What was measured

The proportion of patients demonstrating a clinical benefit (CBR) complete response + partial response + stable disease rates) based on RECIST v1.1.

Analysis population: 54 participants were evaluable

Groups in this outcome

Rad-Let-Met

Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rad-Let-Met54

Reported measurements

CBR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met27Not reportedNot reportedNot reportedNot reported
PR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met15Not reportedNot reportedNot reportedNot reported
SD
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rad-Let-Met12Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        27
    title
    CBR
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        15
    title
    PR
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    SD
denoms
  1. counts
    1. group Id
      OG000
      value
      54
    units
    Participants
description
The proportion of patients demonstrating a clinical benefit (CBR) complete response + partial response + stable disease rates) based on RECIST v1.1.
groups
  1. description
    Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule
    id
    OG000
    title
    Rad-Let-Met
param Type
COUNT_OF_PARTICIPANTS
population Description
54 participants were evaluable
reporting Status
POSTED
time Frame
93 months
title
Clinical Benefit (CBR) Complete Response + Partial Response + Stable Disease Rates) Based on RECIST v1.1.
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice